Abuse of Pharmaceutical Drugs and Its Prevention

doi:10.12116/j.issn.1004-5619.2021.310403

Abstract

Abstract:

Abuse of pharmaceutical drugs is a major public health and social problem worldwide. Mostly abused drugs mainly include opioids such as morphine, tramadol, methadone and fentanyl, sedative-hypnotics such as benzodiazepines and non-benzodiazepines, and central stimulants such as Ritalin （methylphenidate）, Adderall （amphetamine and dextroamphetamine） and modafinil. Abuse of pharmaceutical drugs not only causes direct damage to multiple systems of the body, but also significantly increases risks of mental and physical diseases, imposing a heavy burden on individuals, families and society. Therefore, the prevention and control of pharmaceutical drug abuse are of vital importance. The Chinese government has taken strict administration measures for pharmaceutical drugs with abuse risk. However, confronting endless new drugs and changing abuse trends, it is necessary to further strengthen management and prevention of pharmaceutical drugs, monitor the trend of abuse, establish rapid response mechanisms, popularize relevant knowledge, and develop specific therapeutic drugs and intervention means, in order to promote prevention and treatment of pharmaceutical drug abuse.

Key words: forensic toxicology, drug abuse, pharmaceutical drugs, opioids, sedative-hypnotics, central stimulants, review

CLC Number:

DF795.1

Shi-qiu MENG, Jie SHI. Abuse of Pharmaceutical Drugs and Its Prevention[J]. Journal of Forensic Medicine, 2021, 37(6): 788-795.

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.fyxzz.cn/EN/10.12116/j.issn.1004-5619.2021.310403

http://www.fyxzz.cn/EN/Y2021/V37/I6/788

References 67

1	KARCH S， GOLDBERGER B A. Karch’s drug abuse handbook[M]. 3rd ed. Florida， Boca Raton： CRC Press，2021.
2	PAPAZISIS G， TSAKIRIDIS I， SIAFIS S. Nonmedical use of prescription drugs among medical students and the relationship with illicit drug， tobacco， and alcohol use[J]. Subst Abuse，2018，12：1-3. doi：10.1177/1178221818802298.
3	DRAZDOWSKI T K. A systematic review of the motivations for the non-medical use of prescription drugs in young adults[J]. Drug Alcohol Depend，2016，162：3-25. doi：10.1016/j.drugalcdep.2016.01.011.
4	国家食品药品监督管理总局. 2017年国家药物滥用监测年度报告[R].2018.
	China Food and Drug Administration. Annual report of national drug abuse monitoring in 2017[R]. 2018.
5	陆林. 沈渔邨精神病学[M].6版.北京：人民卫生出版社，2018.
	LU L. Shen YuCun’s psychiatry[M]. 6th ed. Beijing： People’s Medical Publishing House，2018.
6	International Narcotics Control Board. Report of the International Narcotics Control Board for 2019[EB/OL]. （2020-02-27）[2020-12-21]. .
7	WILSON N， KARIISA M， SETH P， et al. Drug and opioid-involved overdose deaths - United States，2017-2018[J]. MMWR Morb Mortal Wkly Rep，2020，69（11）：290-297. doi：10.15585/mmwr.mm6911a4.
8	Centers for Disease Control and Prevention. Opioid basics[EB/OL]. （2021-03-17）[2021-12-21]. .
9	UPADHYAY J， MALEKI N， POTTER J， et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients[J]. Brain，2010，133（Pt 7）：2098-2114. doi：10.1093/brain/awq138.
10	RAHMATI A， SHAKERI R， KHADEMI H， et al. Mortality from respiratory diseases associated with opium use： A population-based cohort study[J]. Thorax，2017，72（11）：1028-1034. doi：10.1136/thoraxjnl-2015-208251.
11	BURR N E， SMITH C， WEST R， et al. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England[J]. Clin Gastroenterol Hepatol，2018，16（4）：534-541.e6. doi：10.1016/j.cgh.2017.10.022.
12	TOBIAS J D， GREEN T P， COTÉ C J， et al. Codeine： Time to say “no”[J]. Pediatrics，2016，138（4）：e20162396. doi：10.1542/peds.2016-2396.
13	KUEHN B M. FDA： No codeine after tonsillectomy for children[J]. JAMA，2013，309（11）：1100. doi：10.1001/jama.2013.2403.
14	SALAS J， SCHERRER J F， SCHNEIDER F D， et al. New-onset depression following stable， slow， and rapid rate of prescription opioid dose escalation[J]. Pain，2017，158（2）：306-312. doi：10.1097/j.pain.0000000000000763.
15	BRENT D A， HUR K， GIBBONS R D. Association between parental medical claims for opioid prescriptions and risk of suicide attempt by their children[J]. JAMA Psychiatry，2019，76（9）：941-947. doi：10.1001/jamapsychiatry.2019.0940.
16	HARDT N， WONG T D， BURT M J， et al. Prevalence of prescription and illicit drugs in pregnancy-associated non-natural deaths of Florida mothers，1999-2005[J]. J Forensic Sci，2013，58（6）：1536-1541. doi：10.1111/1556-4029.12219.
17	MARZUK P M， TARDIFF K， LEON A C， et al. Use of prescription psychotropic drugs among suicide victims in New York City[J]. Am J Psychiatry，1995，152（10）：1520-1522. doi：10.1176/ajp.152.10.1520.
18	PIPER B J， SUAREZ M J， PISERCHIO J P， et al. Illicit and prescription drug misuse as reported to the Maine Diversion Alert Program[J]. Forensic Sci Int，2018，285：65-71. doi：10.1016/j.forsciint.2018.01.025.
19	GEILE J， MAAS A， KRAEMER M， et al. Fatal misuse of transdermal fentanyl patches[J]. Forensic Sci Int，2019，302：109858. doi：10.1016/j.forsciint.2019.06.016.
20	COOPMAN V， CORDONNIER J， PIEN K R， et al. LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic^® transdermal therapeutic systems[J]. Forensic Sci Int，2007，169（2/3）：223-227. doi：10.1016/j.forsciint.2006.03.018.
21	BAKOVIC M， NESTIC M， MAYER D. Death by band-aid： Fatal misuse of transdermal fentanyl patch[J]. Int J Legal Med，2015，129（6）：1247-1252. doi：10.1007/s00414-015-1209-z.
22	KUCZYŃSKA K， GRZONKOWSKI P， KACPR-ZAK Ł， et al. Abuse of fentanyl： An emerging problem to face[J]. Forensic Sci Int，2018，289：207-214. doi：10.1016/j.forsciint.2018.05.042.
23	NARA A， YAMADA C， SAKA K， et al. A fatal case of poisoning with fentanyl transdermal patches in Japan[J]. J Forensic Sci，2019，64（6）：1936-1942. doi：10.1111/1556-4029.14127.
24	张国华，朱宝利，官大威，等. 3例盐酸曲马多药物滥用死亡法医学鉴定分析[J].中国司法鉴定，2008（S2）：83-84.
	ZHANG G H， ZHU B L， GUAN D W， et al. Forensic analysis of 3 death cases caused by tramadol hydrochloride abuse[J]. Zhongguo Sifa Jianding，2008（S2）：83-84.
25	闫春霞，张宏星，马丽霞，等. 85例药物滥用死亡者的法医鉴定及分析[J].中国药物依赖性杂志，2002，11（3）：189-192. doi：10.3969/j.issn.1007-9718.2002.03.009.
	YAN C X， ZHANG H X， MA L X， et al. Forensic identification and analysis of 85 drug abuse deaths[J]. Zhongguo Yaowuyilaixing Zazhi，2002， 11（3）：189-192.
26	KAPIL V， GREEN J L， LE LAIT C， et al. Misuse of benzodiazepines and Z-drugs in the UK[J]. Br J Psychiatry，2014，205（5）：407-408. doi：10.1192/bjp.bp.114.149252.
27	DAVIES J， RAE T C， MONTAGU L. Long-term benzodiazepine and Z-drugs use in England： A survey of general practice [corrected][J]. Br J Gen Pract，2017，67（662）：e609-e613. doi：10.3399/bjgp17x691865.
28	PANES A， PARIENTE A， BÉNARD-LARIBIÈRE A， et al. Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors： A population-based study[J]. Eur Arch Psychiatry Clin Neurosci，2020，270（1）：3-10. doi：10.1007/s00406-018-0966-3.
29	Substance Abuse and Mental Health Services Administration. 2019 National Survey of Drug Use and Health （NSDUH） releases[EB/OL]. [2020-12-21]. .
30	BACHHUBER M A， HENNESSY S， CUNNING-HAM C O， et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States， 1996-2013[J]. Am J Public Health，2016，106（4）：686-688. doi：10.2105/ajph.2016.303061.
31	BLANCO C， HAN B， JONES C M， et al. Prevalence and correlates of benzodiazepine use， misuse， and use disorders among adults in the United States[J]. J Clin Psychiatry，2018，79（6）：18m12174. doi：10.4088/jcp.18m12174.
32	MADRUGA C S， PAIM T L， PALHARES H N， et al. Prevalence of and pathways to benzodia-zepine use in Brazil： The role of depression， sleep， and sedentary lifestyle[J]. Braz J Psychiatry，2019，41（1）：44-50. doi：10.1590/1516-4446-2018-0088.
33	LEE M H， CHOI J W， LEE J， et al. Trends in prescriptions for sedative-hypnotics among Korean adults： A nationwide prescription database study for 2011-2015[J]. Soc Psychiatry Psychiatr Epidemiol，2019，54（4）：477-484. doi：10.1007/s00127-018-1615-x.
34	VICTORRI-VIGNEAU C， GÉRARDIN M， ROUS-SELET M， et al. An update on zolpidem abuse and dependence[J]. J Addict Dis，2014，33（1）：15-23. doi：10.1080/10550887.2014.882725.
35	MOORE T J， MATTISON D R. Assessment of patterns of potentially unsafe use of zolpidem[J]. JAMA Intern Med，2018，178（9）：1275-1277. doi：10.1001/jamainternmed.2018.3031.
36	HAJAK G， MÜLLER W E， WITTCHEN H U， et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone： A review of case reports and epidemiological data[J]. Addiction，2003，98（10）：1371-1378. doi：10.1046/j.1360-0443.2003.00491.x.
37	CHUNG K H， LI C Y， KUO S Y， et al. Risk of psychiatric disorders in patients with chronic insomnia and sedative-hypnotic prescription： A nationwide population-based follow-up study[J]. J Clin Sleep Med，2015，11（5）：543-551. doi：10.5664/jcsm.4700.
38	SABE M， KASHEF H， GIRONI C， et al. Zolpidem stimulant effect： Induced mania case report and systematic review of cases[J]. Prog Neuropsychopharmacol Biol Psychiatry，2019，94：109643. doi：10.1016/j.pnpbp.2019.109643.
39	MCCALL W V， BENCA R M， ROSENQUIST P B， et al. Hypnotic medications and suicide： Risk， mechanisms， mitigation， and the FDA[J]. Am J Psychiatry，2017，174（1）：18-25. doi：10.1176/appi.ajp.2016.16030336.
40	CHOI B， SUNG H G， NAM J H， et al. Zolpidem use and suicide death in South Korea： A population-based case-control study[J]. Suicide Life Threat Behav，2019，49（6）：1653-1667. doi：10.1111/sltb.12548.
41	JUNG S J， LEE J， CHOI J W， et al. Association between sedative-hypnotic medication use and incidence of cancer in Korean Nation Health Insurance Service data[J]. Sleep Med，2019，60：159-164. doi：10.1016/j.sleep.2019.03.018.
42	GAULTON T G， WUNSCH H， GASKINS L J， et al. Preoperative sedative-hypnotic medication use and adverse postoperative outcomes[J]. Ann Surg，2021，274（2）：e108-e114. doi：10.1097/SLA.0000000000003556.
43	WANG L H， LIN H C， LIN C C， et al. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy[J]. Clin Pharmacol Ther，2010，88（3）：369-374. doi：10.1038/clpt.2010.97.
44	SHEEHY O， ZHAO J P， BÉRARD A. Association between incident exposure to benzodiazepines in early pregnancy and risk of spontaneous abortion[J]. JAMA Psychiatry，2019，76（9）：948-957. doi：10.1001/jamapsychiatry.2019.0963.
45	VOLKOW N D. Opioids in pregnancy[J]. BMJ，2016，352：i19. doi：10.1136/bmj.i19.
46	HUYBRECHTS K F， BATEMAN B T， DESAI R J， et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications： Cohort study[J]. BMJ，2017，358：j3326. doi：10.1136/bmj.j3326.
47	SUN E C， DIXIT A， HUMPHREYS K， et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose： Retrospective analysis[J]. BMJ，2017，356：j760. doi：10.1136/bmj.j760.
48	RHEE T G， MAROTTOLI R A， NESS P H VAN， et al. Patterns and perceived benefits of utilizing seven major complementary health approaches in U.S. older adults[J]. J Gerontol A Biol Sci Med Sci，2018，73（8）：1119-1124. doi：10.1093/gerona/gly099.
49	GERLACH L B， OLFSON M， KALES H C， et al. Opioids and other central nervous system-active polypharmacy in older adults in the United States[J]. J Am Geriatr Soc，2017，65（9）：2052-2056. doi：10.1111/jgs.14930.
50	YANG B R， KIM Y J， KIM M S， et al. Prescription of zolpidem and the risk of fatal motor vehicle collisions： A population-based， case-cross-over study from South Korea[J]. CNS Drugs，2018，32（6）：593-600. doi：10.1007/s40263-018-0520-x.
51	TOM S E， WICKWIRE E M， PARK Y， et al. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury[J]. Sleep，2016，39（5）：1009-1014. doi：10.5665/sleep.5742.
52	LAI M M， LIN C C， LIN C C， et al. Long-term use of zolpidem increases the risk of major injury： A population-based cohort study[J]. Mayo Clin Proc，2014，89（5）：589-594. doi：10.1016/j.mayocp.2014.01.021.
53	HEDLUND J， FORSMAN J， STURUP J， et al. Psychotropic medications in Swedish homicide victims and offenders： A forensic-toxicological case-control study of adherence and recreational use[J]. J Clin Psychiatry，2017，78（7）：e797-e802. doi：10.4088/JCP.16m11244.
54	DANCE A. Smart drugs： A dose of intelligence[J]. Nature，2016，531（7592）：S2-S3. doi：10.1038/531S2a.
55	SINGH I， BARD I， JACKSON J. Robust resi-lience and substantial interest： A survey of pharmacological cognitive enhancement among university students in the UK and Ireland[J]. PLoS One，2014，9（10）：e105969. doi：10.1371/journal.pone.0105969.
56	LUCKE J， JENSEN C， DUNN M， et al. Non-medical prescription stimulant use to improve academic performance among Australian university students： Prevalence and correlates of use[J]. BMC Public Health，2018，18（1）：1270. doi：10.1186/s12889-018-6212-0.
57	MAHER B. Poll results： Look who’s doping[J]. Nature，2008，452（7188）：674-675. doi：10.1038/452674a.
58	FRANKE A G， BAGUSAT C， DIETZ P， et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons[J]. BMC Med，2013，11：102. doi：10.1186/1741-7015-11-102.
59	MAIER L J， FERRIS J A， WINSTOCK A R. Pharmacological cognitive enhancement among non-ADHD individuals -- A cross-sectional study in 15 countries[J]. Int J Drug Policy，2018，58：104-112. doi：10.1016/j.drugpo.2018.05.009.
60	MORAN L V， ONGUR D， HSU J， et al. Psychosis with methylphenidate or amphetamine in patients with ADHD[J]. N Engl J Med，2019，380（12）：1128-1138. doi：10.1056/NEJMoa1813751.
61	HUYBRECHTS K F， BRÖMS G， CHRISTENSEN L B， et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations： A cohort study from the international pregnancy safety study consortium[J]. JAMA Psychiatry，2018，75（2）：167-175. doi：10.1001/jamapsychiatry.2017.3644.
62	DAMKIER P， BROE A. First-trimester pregnancy exposure to modafinil and risk of congenital malformations[J]. JAMA，2020，323（4）：374-376. doi：10.1001/jama.2019.20008.
63	KONOVA A B， MOELLER S J， TOMASI D， et al. Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction[J]. JAMA Psychiatry，2013，70（8）：857-868. doi：10.1001/jamapsychiatry.2013.1129.
64	NIELSEN S， MACDONALD T， JOHNSON J L. Identifying and treating codeine dependence： A systematic review[J]. Med J Aust，2018，208（10）：451-461. doi：10.5694/mja17.00749.
65	胡建，陆林. 中国物质使用障碍防治指南[M].北京：中华医学电子音像出版社，2015.
	HU J， LU L. Guidelines for prevention and control of substance use disorder in China[M]. Beijing： Chinese Medical Multimedia Press，2015.
66	POTTER J S， DREIFUSS J A， MARINO E N， et al. The multi-site prescription opioid addiction treatment study： 18-month outcomes[J]. J Subst Abuse Treat，2015，48（1）：62-69. doi：10.1016/j.jsat.2014.07.009.
67	HOOD S D， NORMAN A， HINCE D A， et al. Benzodiazepine dependence and its treatment with low dose flumazenil[J]. Br J Clin Pharmacol，2014，77（2）：285-294. doi：10.1111/bcp.12023.

[1]	Xin-ying WANG, Jia-li ZHANG, Ping XIANG, Xin WANG. Research Progress on Hair Metabolomics and Its Application in Forensic Science [J]. Journal of Forensic Medicine, 2026, 42(1): 49-55.
[2]	Qiong JIA, Kai-jun JIN, Shi-qi LIU, Yi-meng ZHANG, Yun-le MENG, Hao NIE, Sheng HU, Fan YANG, Xing-chun ZHAO, Jian YE. Research Progress on the Methodological System for Decomposition Stage Classification in Forensic Medicine [J]. Journal of Forensic Medicine, 2026, 42(1): 34-42.
[3]	Xin NIU, Zhe CAO. Forensic Significance of Mesenteric Injury in Child Abuse Cases [J]. Journal of Forensic Medicine, 2026, 42(1): 43-48.
[4]	Hang CHEN. Letter to the Editor： On Critical Toxicological Information of Newly Discovered Toxic Substances and Illegal Drugs [J]. Journal of Forensic Medicine, 2026, 42(1): 64-65.
[5]	Ya-ning SUN, Dan-yang LI, Qing XIA, Yan GAO, Zong-shi XU, Wen-tao XIA, Hui-ming ZHOU, Xiao-meng HAN, Xiao-ying YU, Yan-liang SHENG. Frontiers and Perspectives of Artificial Intelligence in Forensic Research on CT Imaging Diagnosis of Rib Fractures [J]. Journal of Forensic Medicine, 2025, 41(6): 593-600.
[6]	Ning-guo LIU. Innovative Development and Future Prospects in Forensic Pathology [J]. Journal of Forensic Medicine, 2025, 41(6): 517-530.
[7]	Hu ZHAO. Current Status and Challenges of Forensic Psychiatry Research [J]. Journal of Forensic Medicine, 2025, 41(6): 531-536.
[8]	Jin-xuan YANG, Dong-an TIAN, Xin-yu TANG, Zhan-ying ZHAO, Xi-yue JING, Dong-mei WANG, Xiao-fei TIAN. The Role of Iron Dysregulation in White Matter Injury Induced by Carbon Mono- xide Poisoning [J]. Journal of Forensic Medicine, 2025, 41(6): 545-551.
[9]	Li-liang LI, Jian-hua ZHANG, Feng CHEN, Rui ZHAO, Ya-dong GUO, Zhen-yuan WANG, Yi-wu ZHOU, Da-wei GUAN, Bin CONG. Expert Consensus on Cause of Death Determinations in Antipsychotics-Related Deaths with Negative Autopsy Findings [J]. Journal of Forensic Medicine, 2025, 41(6): 537-544.
[10]	. Precision Identification from a Multi-omics Perspective： Current Status， Challenges， and Prospects in Forensic Genetics ZHU Bo-feng [J]. Journal of Forensic Medicine, 2025, 41(5): 421-440.
[11]	Han ZHANG, Xin HUANG, An-qi CHEN, Ji CHEN, Yan-fang LU, Jian-ye ZENG, Xiang WANG. Skin Microbiome： Expanding Dimensions and Challenges in Forensic Evidence [J]. Journal of Forensic Medicine, 2025, 41(5): 443-455.
[12]	Hao-jie QIN, Chen MO, Hong-wei LI, Zhi-jiang LIU, Zhe ZHENG. Role of Ferroptosis in Paraquat-Induced Acute Lung Injury in Mice [J]. Journal of Forensic Medicine, 2025, 41(5): 494-501.
[13]	Yan GAO, Fang CHEN, Wen-tao XIA, Xiao-ping YANG, Ze-yu WANG, Ze-ren YANG, Xia LIU, Yan-liang SHENG. Research Progress of Chirp ABR and Its Application in Forensic Auditory Identification [J]. Journal of Forensic Medicine, 2025, 41(4): 387-393.
[14]	Min SHEN. Practice and Reflection on Forensic Toxicology from the Perspective of Evidence Reliability [J]. Journal of Forensic Medicine, 2025, 41(4): 297-306.
[15]	Yi-ming TIAN, Yi-bo YAN, Di WEN, Yan SHI. Research Progress on the Application of Novel Functional Materials for Rapid Detection of New Psychoactive Substances [J]. Journal of Forensic Medicine, 2025, 41(4): 314-325.